Related Experiment Video
Updated: Jun 4, 2026
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Protein kinase inhibitor as a potential candidate for epilepsy treatment
Zita Gajda1, Rita Török, Zoltán Horváth
1Department of Comparative Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary.
Purpose:
Effects of the "VID-82925" kinase inhibitor molecule were investigated both during the developing phase as well as during the stable phase of the focus with spontaneous recurrent seizures using the 4-AP-induced in vivo epilepsy model in anesthetized rats.
Methods:
In electrophysiologic experiments, VID-82925 (0.85 mg/kg) was injected intravenously either before the induction (pretreatment) or after the development of the stable focus (treatment). Reference drugs carbamazepine (4.8 mg/kg) and levetiracetam (50 mg/kg) were employed using the same experimental paradigm. The antiepileptic effect of VID-82925 was also compared to those of the broad-spectrum gap junction channel blocker carbenoxolone (10 mm).
Key Findings:
Pretreatment with VID-82925 revealed an antiepileptogenic effect as it suppressed significantly the manifestation of the epileptiform activity not only during the developing phase, but also for a considerable long period during the stable phase of the focus. The current data do not allow us to differentiate an antiictal treatment effect from an antiepileptogenic effect of the compound during the stable phase of the focus. Treatment with VID-82925 was also effective against ictogenesis during the stable phase of the focus. Pretreatment with levetiracetam failed to exert any antiepileptogenic effect. The antiepileptic effects of VID-82925 and of the reference drugs on the epileptiform activity of the stable focus were comparable in intensity; however, the effect of VID-82925 was 2-3 times longer. The effects of VID-82925 and of carbenoxolone overlapped one another to some extent, suggesting that VID-82925 may exert its effects at least partially through blocking of gap junctional communication.
Significance:
Our results indicate that inhibition of protein kinases may also provide an effective strategy for the development of a drug that is not only antiepileptic but also depresses the course of epileptogenesis.
Insights
The kinase inhibitor VID-82925 shows promise as an antiepileptic and antiepileptogenic drug, suppressing seizure activity and potentially altering disease course. Its effects are comparable to existing treatments but longer-lasting.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
- Developing effective treatments that address both seizure control and the underlying disease progression (epileptogenesis) remains a critical challenge.
- Kinase inhibitors are being explored for their therapeutic potential in neurological conditions.
Purpose of the Study:
- To investigate the antiepileptic and antiepileptogenic effects of the novel kinase inhibitor VID-82925.
- To evaluate VID-82925's efficacy during both the development and stable phases of epilepsy in an in vivo model.
- To compare VID-82925's effects with established antiepileptic drugs and a gap junction blocker.
Main Methods:
- Utilized a 4-aminopyridine (4-AP)-induced in vivo epilepsy model in anesthetized rats.
- Administered VID-82925 intravenously via pretreatment or treatment protocols.
- Compared efficacy against carbamazepine, levetiracetam, and carbenoxolone.
Main Results:
- VID-82925 demonstrated significant antiepileptogenic effects, suppressing epileptiform activity during both developing and stable phases.
- Treatment with VID-82925 was effective against seizures in the established epilepsy model.
- VID-82925's antiepileptic effects were comparable in intensity but 2-3 times longer-lasting than reference drugs, suggesting partial action via gap junction blockade.
Conclusions:
- Inhibition of protein kinases represents a viable strategy for developing novel antiepileptic drugs.
- VID-82925 shows potential not only for seizure control but also for modifying the course of epileptogenesis.
- Further research into kinase inhibitors could lead to more effective epilepsy therapies.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...